keyword
MENU ▼
Read by QxMD icon Read
search

oncology lymphoma

keyword
https://www.readbyqxmd.com/read/28911068/early-stage-mantle-cell-lymphoma-a-retrospective-analysis-from-the-international-lymphoma-radiation-oncology-group-ilrog
#1
B S Dabaja, A D Zelenetz, A K Ng, R W Tsang, S Qi, P K Allen, D Hodgson, U Ricardi, R T Hoppe, R Advani, P M Mauch, L S Constine, L Specht, Y Li, S A Terezakis, A Wirth, G Reinartz, H T Eich, B M P Aleman, P Barr, J Yahalom
Background: Mantle cell lymphoma (MCL) rarely presents as early-stage disease, but clinical observations suggest that patients who present with early-stage disease may have better outcomes than those with advanced-stage disease. Patients and methods: In this 13-institution study, we examined outcomes among 179 patients with early-stage (stage I or II) MCL in an attempt to identify prognostic factors that influence treatment selection and outcome. Variables examined included clinical characteristics, treatment modality, response to therapy, sites of failure, and survival...
September 1, 2017: Annals of Oncology: Official Journal of the European Society for Medical Oncology
https://www.readbyqxmd.com/read/28910997/paediatric-nuclear-medicine-imaging
#2
Lorenzo Biassoni, Marina Easty
Background: Nuclear medicine imaging explores tissue viability and function by using radiotracers that are taken up at cellular level with different mechanism. This imaging technique can also be used to assess blood flow and transit through tubular organs. Nuclear medicine imaging has been used in paediatrics for decades and this field is continuously evolving. Sources of data: The data presented comes from clinical experience and some milestone papers on the subject...
September 1, 2017: British Medical Bulletin
https://www.readbyqxmd.com/read/28906402/barriers-and-facilitators-to-participation-in-clinical-trial-among-lymphoma-patients-from-sun-yat-sen-university-cancer-center-in-china-an-observation-study
#3
Qiuhuan Kong, Hua Mei, Yuerong Lai, Simei Shi, Yaner Li, Lianzhu He, Hui-Ying Qin
Recruitment rate of clinical trials in cancer patients is pretty low in China. Little is known about factors influencing trial recruitment in Chinese cancer patients. The aim of present study is to evaluate the barriers and facilitators to participation in clinical trials among lymphoma patients in China.From December 2014 to August 2015, the survey was carried out in the Department of Medical Oncology in Sun Yat-sen University Cancer Center. A self-made questionnaire was used among lymphoma patients (N = 331) to evaluate their attitude toward clinical trials...
September 2017: Medicine (Baltimore)
https://www.readbyqxmd.com/read/28902390/outcomes-in-adolescents-and-young-adults-with-hodgkin-lymphoma-treated-on-us-cooperative-group-protocols-an-adult-intergroup-e2496-and-children-s-oncology-group-cog-ahod0031-comparative-analysis
#4
Tara O Henderson, Susan K Parsons, Kristen E Wroblewski, Lu Chen, Fangxin Hong, Sonali M Smith, Jennifer L McNeer, Ranjana H Advani, Randy D Gascoyne, Louis S Constine, Sandra Horning, Nancy L Bartlett, Bijal Shah, Joseph M Connors, John I Leonard, Brad S Kahl, Kara M Kelly, Cindy L Schwartz, Hongli Li, Jonathan W Friedberg, Debra L Friedman, Leo I Gordon, Andrew M Evens
BACKGROUND: There is no clear consensus between pediatric and adult providers about the treatment of adolescents and young adults (AYAs) with Hodgkin lymphoma (HL). METHODS: Failure-free survival (FFS) and overall survival (OS) were compared between 114 patients ages 17 to 21 years with HL who were treated on the Eastern Cooperative Oncology Group-American College of Radiology Imaging Network Intergroup adult E2496 study and 391 similarly patients ages 17 to 21 years with HL who were treated on the pediatric Children's Oncology Group (COG) AHOD0031 study...
September 13, 2017: Cancer
https://www.readbyqxmd.com/read/28899972/facts-and-hopes-in-immunotherapy-of-lymphoma-and-myeloma
#5
Matthew J Pianko, Alison J Moskowitz, Alexander M Lesokhin
Immune checkpoint blockade has driven a revolution in modern oncology, and robust drug development of immune checkpoint inhibitors is underway in both solid tumors and hematologic malignancies. High response rates to programmed cell death 1 (PD-1) blockade using nivolumab or pembrolizumab in classical Hodgkin lymphoma (cHL) and several variants of non-Hodgkin lymphoma (NHL) revealed an intrinsic biologic sensitivity to this approach, and work is ongoing exploring combinations with immune checkpoint inhibitors in both cHL and NHL...
September 12, 2017: Clinical Cancer Research: An Official Journal of the American Association for Cancer Research
https://www.readbyqxmd.com/read/28894396/a-validation-of-clinical-data-captured-from-a-novel-cancer-care-quality-program-directly-integrated-with-administrative-claims-data
#6
David M Kern, John J Barron, Bingcao Wu, Alex Ganetsky, Vincent J Willey, Ralph A Quimbo, Michael J Fisch, Joseph Singer, Ann Nguyen, Ronac Mamtani
BACKGROUND: Data from a Cancer Care Quality Program are directly integrated with administrative claims data to provide a level of clinical detail not available in claims-based studies, and referred to as the HealthCore Integrated Research Environment (HIRE)-Oncology data. This study evaluated the validity of the HIRE-Oncology data compared with medical records of breast, lung, and colorectal cancer patients. METHODS: Data elements included cancer type, stage, histology (lung only), and biomarkers...
2017: Pragmatic and Observational Research
https://www.readbyqxmd.com/read/28881619/mrna-in-exosomas-as-a-liquid-biopsy-in-non-hodgkin-lymphoma-a-multicentric-study-by-the-spanish-lymphoma-oncology-group
#7
Mariano Provencio, Marta Rodríguez, Blanca Cantos, Pilar Sabín, Cristina Quero, Francisco R García-Arroyo, Antonio Rueda, Constanza Maximiano, Delvys Rodríguez-Abreu, Antonio Sánchez, Javier Silva, Vanesa García
PURPOSE: To determine the feasibility of mRNAs (C-MYC, BCL-XL, BCL-6, NF-κβ, PTEN and AKT) in exosomes of plasma as a liquid biopsy method for monitoring and prognostic evolution in B-cell lymphomas. PATIENTS AND METHODS: Exosomes were isolated from 98 patients with B-cell Lymphoma and 68 healthy controls. mRNAs were analyzed by quantitative PCR. An additional 31 post-treatment samples were also studied. RESULTS: In the general and follicular lymphoma series, the presence of AKT mRNA was associated with poor response to rituximab-based treatment...
August 1, 2017: Oncotarget
https://www.readbyqxmd.com/read/28880625/biosimilar-monoclonal-antibodies-mabs-in-oncology
#8
Caroline Moore
Biological medicines are derived from living cells and organisms. Monoclonal antibodies (mAbs) are biological agents that are widely used to treat malignancies including non-Hodgkin's lymphomas and chronic lymphocytic leukaemia. They are effective but expensive. The patents for many mAbs are expiring, so biosimilar medicines, which contain a version of the active ingredient of the original drug, are being developed. Biological medicines cannot be assessed in the same way as standard generic medications because they are difficult to copy and can change over time...
September 7, 2017: British Journal of Nursing: BJN
https://www.readbyqxmd.com/read/28875091/demographics-of-head-and-neck-cancer-patients-a-single-institution-experience
#9
George S Stoyanov, Martina Kitanova, Deyan L Dzhenkov, Peter Ghenev, Nikolay Sapundzhiev
Introduction Head and neck cancer (HNC) comprises a diverse group of oncological entities, originating from various tissue types and organ localizations, situated in the topographical regions of the head and neck (H&N). This single institution retrospective study was aimed at establishing the HNC patient demographics and categorizing the individual incidence of H&N malignancies, regarding their organ of origin and main histopathological type. Materials and methods All histologically verified cases of HNC from a single tertiary referral center were reviewed in a descriptive retrospective manner...
July 2, 2017: Curēus
https://www.readbyqxmd.com/read/28874597/risk-of-febrile-neutropenia-associated-with-select-myelosuppressive-chemotherapy-regimens-in-a-large-community-based-oncology-practice
#10
Yanli Li, Leila Family, Su-Jau Yang, Zandra Klippel, John H Page, Chun Chao
Background: NCCN has classified commonly used chemotherapy regimens into high (>20%), intermediate (10%-20%), or low (<10%) febrile neutropenia (FN) risk categories based primarily on clinical trial evidence. Many chemotherapy regimens, however, remain unclassified by NCCN or lack FN incidence data in real-world clinical practice. Patients and Methods: We evaluated incidence proportions of FN and grade 4 and 3/4 neutropenia during the first chemotherapy course among patients from Kaiser Permanente Southern California who received selected chemotherapy regimens without well-established FN risk...
September 2017: Journal of the National Comprehensive Cancer Network: JNCCN
https://www.readbyqxmd.com/read/28872997/treatment-of-tumor-lysis-syndrome-in-children-with-leukemia-lymphoma-in-resource-limited-settings-efficacy-of-a-fixed-low-dose-rasburicase
#11
K G Gopakumar, Priyakumari Thankamony, Shwetha Seetharam, Kusumakumary P
Rasburicase is a novel drug used during the management of tumor lysis syndrome. In countries with limited resources, it is frequently given at a lower dose and only for the treatment of established tumor lysis syndrome and not as prophylaxis. A retrospective study was conducted in the department of pediatric oncology at a tertiary referral oncology center in south India to analyze the use of rasburicase over the past 3 years. Data of all the 18 children (< 14 years of age) who were given rasburicase for the management of hyperuricemia were collected and analyzed...
September 5, 2017: Pediatric Hematology and Oncology
https://www.readbyqxmd.com/read/28871325/high-level-of-soluble-interleukin-2-receptor-in-serum-predicts-treatment-resistance-and-poor-progression-free-survival-in-multiple-myeloma
#12
Liang Wang, Jing-Hua Wang, Wen-Jian Liu, Wei-da Wang, Hua Wang, Xiao-Qin Chen, Qi-Rong Geng, Yue Lu, Zhong-Jun Xia
The IL-2/IL-2 receptor (IL-2R) system plays a central role in maintaining normal T cell immunity, and its disturbance is associated with several hematologic disorders. Studies have found in several types of lymphoma that abnormal amounts of soluble IL-2R (sIL-2R) may result in imbalance of the IL-2/IL-2R system and hence of the T cell immunoregulation. Whether the level of sIL-2R in blood could predict treatment outcomes or not needs to be investigated in multiple myeloma (MM) patients. The level of sIL-2R in serum was measured using enzyme-linked immunosorbent assay (ELISA) in 81 patients with newly diagnosed MM...
September 5, 2017: Annals of Hematology
https://www.readbyqxmd.com/read/28867732/comparison-between-antiemetic-effects-of-palonosetron-and-granisetron-on-chemotherapy-induced-nausea-and-vomiting-in-japanese-patients-treated-with-r-chop
#13
Mayako Uchida, Yasuo Mori, Tsutomu Nakamura, Koji Kato, Kenjiro Kamezaki, Katsuto Takenaka, Motoaki Shiratsuchi, Kaori Kadoyama, Toshihiro Miyamoto, Koichi Akashi
In the present study, the antiemetic effect of palonosetron, not combined with dexamethasone and aprepitant, on chemotherapy-induced nausea and vomiting was evaluated in patients with malignant lymphoma receiving first-line rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) therapy, and was compared to that of granisetron. A total of 74 patients with non-Hodgkin lymphoma were included in this study (April 2007 to December 2015). Palonosetron (0.75 mg) or granisetron (3 mg) was intravenously administered before R-CHOP therapy...
2017: Biological & Pharmaceutical Bulletin
https://www.readbyqxmd.com/read/28866351/human-t-cell-leukemia-virus-type-i-tax-genotype-analysis-in-okinawa-the-southernmost-and-remotest-islands-of-japan-different-distributions-compared-with-mainland-japan-and-the-potential-value-for-the-prognosis-of-aggressive-adult-t-cell-leukemia-lymphoma
#14
Shugo Sakihama, Mineki Saito, Megumi Kuba-Miyara, Takeaki Tomoyose, Naoya Taira, Takashi Miyagi, Masaki Hayashi, Shigeko Kinjo, Sawako Nakachi, Iori Tedokon, Yukiko Nishi, Keita Tamaki, Kazuho Morichika, Jun-Nosuke Uchihara, Satoko Morishima, Ken-Nosuke Karube, Yuetsu Tanaka, Hiroaki Masuzaki, Takuya Fukushima
Okinawa, comprising remote islands off the mainland of Japan, is an endemic area of human T-cell leukemia virus type I (HTLV-1), the causative virus of adult T-cell leukemia-lymphoma (ATL) and HTLV-1-associated myelopathy (HAM). We investigated the tax genotype of HTLV-1 among 29 HTLV-1 carriers, 74 ATL patients, and 33 HAM patients in Okinawa. The genotype distribution-60 (44%) taxA cases and 76 (56%) taxB cases-differed from that of a previous report from Kagoshima Prefecture in mainland Japan (taxA, 10%; taxB, 90%)...
August 18, 2017: Leukemia Research
https://www.readbyqxmd.com/read/28857136/results-of-a-multicentre-uk-wide-retrospective-study-evaluating-the-efficacy-of-brentuximab-vedotin-in-relapsed-refractory-classical-hodgkin-lymphoma-in-the-transplant-naive-setting
#15
Toby A Eyre, Elizabeth H Phillips, Kim M Linton, Shireen Kassam, Adam Gibb, Suzanne Allibone, John Radford, Karl Peggs, Cathy Burton, Gillian Stewart, Rifca LeDieu, Catherine Booth, Wendy L Osborne, Fiona Miall, David W Eyre, Kirit M Ardeshna, Graham P Collins
Relapsed or refractory classical Hodgkin lymphoma (cHL) is associated with a poor outcome when standard chemotherapy fails. Brentuximab vedotin (BV) is an anti-CD30 monoclonal antibody-drug conjugate licensed for use at relapse after autologous stem cell transplant (ASCT) or following two prior therapies in those unsuitable for ASCT. There are limited data assessing the ability of BV to enable curative SCT. We performed a UK-wide retrospective study of 99 SCT-naïve relapsed/refractory cHL. All had received 2 prior lines and were deemed fit for transplant but had an insufficient remission to proceed...
August 31, 2017: British Journal of Haematology
https://www.readbyqxmd.com/read/28837125/highlights-in-aggressive-non-hodgkin-lymphoma-from-the-2017-american-society-of-clinical-oncology-annual-meeting-commentary
#16
Frederick L Locke
No abstract text is available yet for this article.
August 2017: Clinical Advances in Hematology & Oncology: H&O
https://www.readbyqxmd.com/read/28837124/highlights-in-aggressive-non-hodgkin-lymphoma-from-the-2017-american-society-of-clinical-oncology-annual-meeting
#17
(no author information available yet)
No abstract text is available yet for this article.
August 2017: Clinical Advances in Hematology & Oncology: H&O
https://www.readbyqxmd.com/read/28832957/outcomes-in-370-patients-with-mantle-cell-lymphoma-treated-with-ibrutinib-a-pooled-analysis-from-three-open-label-studies
#18
Simon Rule, Martin Dreyling, Andre Goy, Georg Hess, Rebecca Auer, Brad Kahl, Nora Cavazos, Black Liu, Shiyi Yang, Fong Clow, Jenna D Goldberg, Darrin Beaupre, Jessica Vermeulen, Mark Wildgust, Michael Wang
Ibrutinib is highly active in treating mantle cell lymphoma (MCL), an aggressive B-cell lymphoma. We pooled data from three ibrutinib studies to explore the impact of baseline patient characteristics on treatment response. Patients with relapsed/refractory MCL (n = 370) treated with ibrutinib had an objective response rate (ORR) of 66% (20% complete response; 46% partial response); median duration of response (DOR), progression-free survival (PFS) and overall survival (OS) were 18·6, 12·8 and 25·0 months, respectively...
August 18, 2017: British Journal of Haematology
https://www.readbyqxmd.com/read/28832891/outcome-of-cancer-related-seizures-in-patients-treated-with-lacosamide
#19
M Toledo, A Molins, M Quintana, E Santamarina, F Martinez-Ricarte, E Martínez-Saez, J Salas-Puig
OBJECTIVES: Lacosamide is an antiepileptic drug (AED), which has proven to be effective to control seizures, including acute conditions such as status epilepticus. The aim of this study is to describe the clinical experience with lacosamide in neuro-oncological patients. MATERIALS AND METHODS: Multicenter retrospective study in patients with cancer-related seizures, who received lacosamide as an add-on therapy. RESULTS: Forty-eight patients with benign and malignant tumors, including primary brain tumors, lymphomas, systemic cancer with central nervous system involvement, or paraneoplastic encephalitis, were included...
August 22, 2017: Acta Neurologica Scandinavica
https://www.readbyqxmd.com/read/28829592/5-4-6-dimorpholino-1-3-5-triazin-2-yl-4-trifluoromethyl-pyridin-2-amine-pqr309-a-potent-brain-penetrant-orally-bioavailable-pan-class-i-pi3k-mtor-inhibitor-as-clinical-candidate-in-oncology
#20
Florent Beaufils, Natasa Cmiljanovic, Vladimir Cmiljanovic, Thomas Bohnacker, Anna Melone, Romina Marone, Eileen Jackson, Xuxiao Zhang, Alexander Sele, Chiara Borsari, Jürgen Mestan, Paul Hebeisen, Petra Hillmann, Bernd Giese, Marketa Zvelebil, Doriano Fabbro, Roger L Williams, Denise Rageot, Matthias P Wymann
Phosphoinositide 3-kinase (PI3K) is deregulated in a wide variety of human tumors and triggers activation of protein kinase B (PKB/Akt) and mammalian target of rapamycin (mTOR). Here we describe the preclinical characterization of compound 1 (PQR309, bimiralisib), a potent 4,6-dimorpholino-1,3,5-triazine-based pan-class I PI3K inhibitor, which targets mTOR kinase in a balanced fashion at higher concentrations. No off-target interactions were detected for 1 in a wide panel of protein kinase, enzyme, and receptor ligand assays...
September 1, 2017: Journal of Medicinal Chemistry
keyword
keyword
63324
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"